Patent intelligence · CA
CA 2851492
COMPOSITIONS OPHTALMIQUES EN GEL
COMPOSITIONS OPHTALMIQUES EN GEL
Patent details — CA 2851492
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Mar 28, 2013
- Expiration
- Mar 23, 2033
- Applicant
- BAUSCH & LOMB [US]
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 10 A I, A61K 31/ 56 A I, A61K 47/ 02 A I
Quick answer
CA 2851492 (COMPOSITIONS OPHTALMIQUES EN GEL) is held by BAUSCH & LOMB [US]. Status: granted. Granted Mar 28, 2013. Expires Mar 23, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAUSCH & LOMB [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 10 A I, A61K 31/ 56 A I, A61K 47/ 02 A I, A61K 47/ 32 A I, A61K/3156
More from BAUSCH & LOMB [US]
Related pharmaceutical patents in our USPTO index.
-
US 2020339710
GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF
granted -
US 2020239601
CROSSLINKED POLYMERIC NETWORK AND USE THEREOF
granted -
US 2019151500
OPHTHALMIC VISCOELASTIC COMPOSITIONS
granted -
CA 3043000
DERIVES DE PROSTAGLANDINE LIBERANT DE L'OXYDE NITRIQUE POUR LE TRAITEMENT DU GLAUCOME A TENSION NORMALE
granted -
US 2016213609
OPHTHALMIC SUSPENSION COMPOSITION
granted -
US 2015038439
METHOD FOR PREPARING SUSPENSIONS OF LOW-SOLUBILITY MATERIALS
granted -
US 2014206764
Poly(Nitrogen/Amine) Derivatives of a Natural Wax and Ophthalmic Compositions
granted -
US 2014142182
Aqueous Liquid Composition Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid
granted
Frequently asked questions
What is US patent 2851492?
CA 2851492 (COMPOSITIONS OPHTALMIQUES EN GEL) is held by BAUSCH & LOMB [US]. Status: granted. Granted Mar 28, 2013. Expires Mar 23, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2851492?
BAUSCH & LOMB [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 2851492 expire?
Our index shows an expiration date of Mar 23, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.